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Abstract 22 
Members of the mitochondrial carrier family (SLC25) transport a variety of compounds 23 
across the inner membrane of mitochondria. These transport steps provide building blocks 24 
for the cell and link the pathways of the mitochondrial matrix and cytosol. An increasing 25 
number of diseases and pathologies has been associated with their dysfunction. In this 26 
review, the molecular basis of these diseases is explained based on our current 27 
understanding of their transport mechanism. 28 
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The inner membrane of mitochondria is highly impermeable to molecules and ions, which is 34 
a key property required for energy conversion in oxidative phosphorylation. Therefore, a 35 
large number of transport proteins and channels are required to transport molecules and 36 
ions across this membrane to link cytosolic and mitochondrial metabolism, and to provide 37 
compounds for building and maintenance of the mitochondrion and the cell. In fact, all 38 
major food groups pass through the mitochondrion as part of central metabolism, including 39 
the degradation products of fats, sugars, and proteins as well as nucleotides, vitamins and 40 
inorganic ions (FIGURE 1). Most of the transport steps are carried out by members of the 41 
mitochondrial carrier family (SLC25), the topic of this review, but there also other 42 
transporter families, such as the mitochondrial pyruvate carrier (SLC54) (19, 61), 43 
sideroflexins (SLC56) (87, 127, 170) and mitochondrial ABC transporters (98, 148). 44 
Mitochondrial carriers provide key transport steps in a variety of metabolic pathways, such 45 
as the oxidation of degradation products of fats and sugars, the degradation, synthesis and 46 
interconversion of amino acids, and the synthesis of iron sulfur clusters and heme, but also 47 
in ion homeostasis, mitochondrial macromolecular synthesis, heat production, 48 
mitochondrial dynamics, signaling, cellular differentiation, development, and cell death (89, 49 
123). The genes of 53 mitochondrial carriers of the SLC25 family have been identified in the 50 
human genome (89, 123), based on their shared sequence features (137, 147) and structural 51 
properties (128, 141, 143, 144). Most carriers are found in the inner membrane of the 52 
mitochondrion, but an adenine nucleotide transporter (SLC25A17) has been located in the 53 
peroxisome, where it supplies ATP for energy-requiring processes (161). Moreover, two 54 
highly divergent carriers, SLC25A46 and SLC25A50 (MTCH2), have been localized to the outer 55 
membrane of the mitochondrion (2, 172), where they might have some involvement in 56 
mitochondrial dynamics and apoptosis, respectively, but no transport function has been 57 
assigned to them. 58 
 Mitochondrial carriers are functional as monomers (10-12, 32, 91). The only 59 
confirmed exception is the mitochondrial aspartate/glutamate carrier, which is a structural 60 
dimer through the interactions of the N-terminal calcium regulatory domains, but the carrier 61 
domains, which are involved in transport, function separately (see further below) (157). 62 
Recently, a claim was made for the bovine mitochondrial ADP/ATP carrier being monomeric 63 
and dimeric using native mass spectrometry of intact membranes (28), but the reported 64 
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mass deviates significantly from those observed by others (7, 62, 153). To account for the 65 
difference, the carrier was proposed to have an unusually large number of modifications, 66 
which have not been observed in other studies (7, 153) or in the structure (128). 67 
Furthermore, the species observed by native mass spectrometry lacks three tightly bound 68 
cardiolipin molecules (28), which are observed consistently in other studies (10, 14, 96, 128, 69 
141, 142).  70 
Given the central role of mitochondrial carriers in cellular metabolism and 71 
physiology, it is not surprising that mutations in mitochondrial carriers have been associated 72 
with a large number of pathologies. Due to recent advances in sequencing technologies, this 73 
number is likely to rise rapidly, as new links to disease are discovered frequently, including 74 
for mitochondrial carriers that have no assigned function yet. Although originally thought to 75 
be relatively rare, it is now clear that pathologies involving mitochondrial carriers may be 76 
among the most prevalent of all mitochondrial diseases. For example, citrin deficiency, 77 
which is caused by disease variants of the mitochondrial aspartate/glutamate carrier 78 
(SLC25A13), has a very high frequency in Far Eastern populations (146). Current estimates, 79 
based on pathogenic allele frequencies, are 1:17,000 in Japan and China, 1:9,000 in Taiwan, 80 
and 1:50,000 in Korea, but the disease has now also been discovered in other populations, 81 
making it panethnic (38, 122). With few exceptions most pathologies are inherited in an 82 
autosomal recessive manner. The phenotypic manifestation of these pathologies is highly 83 
variable, starting at different ages, affecting various organs in different ways, and is 84 
dependent on the type of mutation, i.e. deletion, missense, nonsense, inversion, or splice-85 
site mutation. The pathologies can be broadly divided into developmental, metabolic and 86 
neuromuscular diseases. Understanding the molecular basis for these diseases is vital for 87 
diagnosis and prognosis of the disease, and for development of effective treatments and 88 
therapies. 89 
 90 
In this review, we provide a comprehensive overview of the role of mitochondrial 91 
carriers in physiology and pathology. We describe all pathogenic missense mutations that 92 
have been identified to date in the context of new insights into the structural mechanism of 93 
these transport proteins. This analysis can be used to predict with better accuracy which 94 
mutations are likely to be pathological, resulting in a dysfunctional mitochondrial carrier. 95 
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The data presented in this review may also help to identify new pathological variants and 96 
associated mitochondrial diseases. 97 
 98 
The role of mitochondrial carriers in physiology and pathology 99 
With its 53 members, the mitochondrial carrier family SLC25 is the largest solute transporter 100 
family in humans. Here, we first briefly review the function of the known human 101 
mitochondrial carriers in cellular physiology and pathology, but for more detailed 102 
information the reader is referred here (124). 103 
 104 
Nucleotide transport  105 
Mitochondria require nucleotides for a host of important functions, such as the synthesis of 106 
ATP, mitochondrial RNA and DNA synthesis, enzymatic reactions, and regulation. The best-107 
known member of the SLC25 family is the mitochondrial ADP/ATP carrier, also called 108 
adenine nucleotide translocase or translocator (ANT). The carrier imports ADP into the 109 
mitochondrial matrix, where it is converted to ATP by ATP synthase, and exports the newly 110 
synthesized ATP to the cytosol, where it fuels the metabolic energy-requiring processes that 111 
are vital for cell survival (7, 83, 90, 144). There are four different paralogs in humans, AAC1, 112 
AAC2, AAC3 and AAC4 (SLC25A4, SLC25A5, SLC25A6 and SLC25A31, respectively), which are 113 
expressed in a tissue-dependent manner (FIGURE 1A) (31, 40, 88, 115). The mitochondrial 114 
ADP/ATP carriers carry out equimolar exchange of ADP and ATP, and thus do not alter the 115 
total adenine nucleotide pool in the mitochondrial matrix. The mitochondrial ADP/ATP 116 
carrier has been extensively characterized structurally (FIGURE 2A) (128, 141-144). In the 117 
absence of adenine nucleotides and in the presence of fatty acids, the mitochondrial 118 
ADP/ATP carrier may function as an uncoupling protein, transporting protons (13, 20), but a 119 
molecular mechanism is lacking. 120 
The human mitochondrial ADP/ATP carrier AAC1 (SLC25A4) has three associated 121 
pathologies, which are quite different in nature: (i) late onset dominant progressive external 122 
ophthalmoplegia with mitochondrial DNA deletions (OMIM 609283) (77), (ii) recessive 123 
mitochondrial DNA depletion syndrome (OMIM 615418) (53, 125), and (iii) early-onset 124 
dominant de novo mutations leading to mitochondrial disease, varying from lethal to mild 125 
severity (OMIM 103220) (81, 158). The complexity of the genetics underlying these three 126 
diseases has not been fully explained. As will be shown below, the carrier has all the features 127 
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required for its transporter function, so the dominant inheritance cannot be explained by 128 
dimerization, as was thought previously (91). This notion is supported further by the fact 129 
that the early-onset dominant disease mutations involve key functional residues on the 130 
inside of the carrier, which cannot be involved in dimerization (158). Every day the ADP/ATP 131 
carriers transport approximately our own body weight in ADP and ATP across the inner 132 
membrane of mitochondria, meaning that the dominant inheritance could well be explained 133 
by haplo-insufficiency. In agreement, the early-onset de novo dominant mutations affect 134 
highly conserved residues that are central to the transport mechanism (p.Lys33Gln, 135 
p.Arg80His and p.Arg235Gly), whereas late-onset domain mutations affect non-conserved 136 
residues on the periphery of the protein without an obvious role in the mechanism (e.g. 137 
p.Ala90Asp, p.Asp104Gly, Leu98Pro, and Ala114Pro). Not fitting this genetic explanation are 138 
the recessive mutations, which lead to mitochondrial DNA deletions and mitochondrial 139 
disease only in homozygotes, whereas the heterozygotes are unaffected (53), but they may 140 
give rise to biogenesis rather than functional issues (e.g. p.Ala123Asp, p.Arg263Pro). 141 
However, it would be impossible for humans to live without functional ADP/ATP carriers, as 142 
cells would be reliant on glycolysis and fermentation alone, providing low yields of ATP. The 143 
oxidative phosphorylation of sugars, fats and amino acids in mitochondria is critically 144 
dependent on ADP/ATP carriers. This notion is supported by the fact that the powerful 145 
inhibitors carboxyatractyloside and bongkrekic acid kill humans, showing that human life 146 
cannot sustain itself without mitochondrial ADP/ATP transport. There are three other 147 
paralogs of the mitochondrial ADP/ATP carrier, AAC2, AAC3, and AAC4, which are expressed 148 
at different levels and/or may be upregulated to compensate for the missing transport 149 
activity in homozygous recessive patients. In addition, there are the four paralogs of the 150 
ATP-Mg/Pi carrier and some vitamin transporters, such as the CoA transporter (SLC25A42) 151 
(51) and thiamine pyrophosphate carrier (SLC25A19) (39), which can also transport adenine 152 
nucleotides in addition to their key substrates. The complexity of adenine nucleotide 153 
transport might explain viability in the homozygous recessive cases and the variation in 154 
severity and onset of the pathogenicity in the heterozygous dominant cases (81, 158). The 155 
mitochondrial ADP/ATP carrier can also transport the deoxy forms of ADP and ATP, which 156 
are required for mitochondrial DNA replication, which could explain the role of disease 157 
variants in mitochondrial DNA deletions and maintenance, aside from the production of ATP. 158 
Finally, very little is known about the effect of these mutations on the biogenesis of the 159 
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disease variants. Therefore, other genetic mechanisms, such as gain of function through 160 
aggregation, are also pursued as an explanation (100, 101). However, it is clear that this 161 
important issue is unresolved, requiring a more complete picture of adenine nucleotide 162 
transport in mitochondria. 163 
The net import and export of adenine nucleotides is carried out by mitochondrial 164 
ATP-Mg/Pi carriers, which exchange phosphate for adenine nucleotides, coupled to 165 
magnesium or protons, in an electroneutral way (8, 36, 45). This transport activity allows the 166 
mitochondrion to respond to changes in energetic demand and to replenish adenine 167 
nucleotide pools after mitochondrial division and macromolecular synthesis (8, 26, 45). 168 
There are three human paralogs APC1 (SLC25A24), APC2 (SLC25A23), APC3 (SLC25A25), 169 
which are calcium-regulated (5, 45), and a fourth isoform APC4 (SLC25A41), which is not 170 
(160) (FIGURE 1B). APC1-3 have three domains; (i) an N-terminal calcium-regulatory domain 171 
with four calcium-binding EF-hands, (ii) an amphipathic helix and (iii) a C-terminal carrier 172 
domain (59) (FIGURE 2B). In the current model of calcium regulation, the amphipathic helix 173 
is bound to the regulatory domain in the presence of calcium, allowing transport by the 174 
carrier domain to occur (59, 169). In the absence of calcium, the amphipathic helix is 175 
released from the regulatory domain and binds to the carrier domain, leading to inhibition of 176 
transport (58, 60). APC4 lacks both the N-terminal calcium-regulatory domain and the 177 
amphipathic helix (160), which accounts for the absence of calcium regulation.  178 
Dysfunction of the mitochondrial Mg-ATP/phosphate carrier APC1 (SLC25A24) leads 179 
to Fontaine Progeroid Syndrome, also described as Gorlin–Chaudhry–Moss or Fontaine–180 
Farriaux syndrome (43, 138, 145, 168) (OMIM 612289). The mutations are spontaneous 181 
rather than inherited, and lead to a developmental disease, which is characterized by 182 
prenatal and postnatal growth retardation, failure to thrive, a lack of subcutaneous adipose 183 
tissue, premature closure of certain skull bones (coronal craniosynostosis) and short distal 184 
phalanges of the fingers and toes. Other clinical features include abnormal hair patterns, 185 
skin agenesis, umbilical hernia and progeroid facial appearance. APC1 variants are expressed 186 
in mitochondria, and they affect both the mitochondrial morphology and cell viability. There 187 
is also a decrease in mitochondrial ATP synthesis in fibroblasts, but only under stress 188 
conditions (168). The disease variants have not been characterized with respect to folding 189 
and transport function. Interestingly, the paralogue APC3 (SLC25A25) has been implicated in 190 
left-right determination during development and is regulated by TRPP2 ion channels (64), 191 
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showing that the Mg-ATP/phosphate carrier are also playing an important role in 192 
development. 193 
There are two pyrimidine nucleotide carriers in humans (PNC1, SLC25A33 and PNC2, 194 
SLC25A36), which are required for mitochondrial DNA and RNA synthesis and breakdown 195 
(37, 52) (FIGURE 1C). SLC25A33 transports uracil, thymine, and cytosine (deoxy)nucleoside 196 
di- and tri-phosphates by an antiport mechanism, whereas SLC25A36 translocates both 197 
cytosine and uracil (deoxy)nucleoside mono-, di and tri-phosphates using a uniport or 198 
antiport mechanism (37, 52). Both carriers also transport guanine nucleotides, but not 199 
adenine (deoxy)nucleotides. It has also been claimed that the pyrimidine carriers are 200 
involved in the uptake of zinc ions (85), even though several dedicated zinc transporters are 201 
likely to exist in mitochondria. In yeast, a separate mitochondrial GTP/GDP carrier has been 202 
identified (162), but an equivalent transporter has not been identified in humans. The most 203 
closely related carriers by sequence comparison are SLC25A51 and SLC25A52 (137), but no 204 
experimental data are available to support this notion. So far, no disease variants of PNC1 205 
and 2 have been identified. 206 
 207 
Amino acid transport 208 
Amino acids need to be transported into mitochondria for mitochondrial protein synthesis 209 
and for amino acid interconversion and degradation, which can generate metabolic energy. 210 
Several mitochondrial amino acid transporters have been identified, but some are still 211 
missing, importantly those for tryptophan, tyrosine, phenylalanine, methionine, glutamine, 212 
asparagine and cysteine (FIGURE 1D). 213 
The mitochondrial aspartate/glutamate carriers import glutamate and a proton, and 214 
they export aspartate from the mitochondrial matrix (9, 16, 18). AGC1 (SCL25A12, aralar) 215 
and AGC2 (SLC25A13, citrin) are expressed in excitable and non-excitable tissues, 216 
respectively, and play important roles in the malate-aspartate shuttle (FIGURE 1E), 217 
gluconeogenesis, purine and pyrimidine synthesis, the urea cycle (AGC2) (FIGURE 1F) and 218 
myelin synthesis (AGC1) (126). They have an unusual three-domain structure, consisting of 219 
(i) a N-terminal calcium-regulatory domain, (ii) a carrier domain, and (iii) a C-terminal 220 
amphipathic helix (157) (FIGURE 2C). The N-terminal domain has eight EF-hand domains, but 221 
only EF-hand 2 is capable of binding calcium, whereas EF-hands 4-8 are involved in 222 
dimerization, generating a structural homo-dimer (FIGURE 2C). In the calcium-bound state, 223 
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the amphipathic helix is bound to the regulatory domain, whereas in the absence of calcium 224 
the amphipathic helix is released (157), but the mechanism of regulation is not fully 225 
resolved. 226 
Mutations of the gene coding for the liver paralog AGC2 (SLC25A13) causes neonatal 227 
and/or adult-onset type-II citrullinemia (OMIM 603859), an autosomal recessive disease 228 
characterized by hyperammonemia and citrullinemia, because of a dysfunctional urea cycle, 229 
as well as neuropsychiatric symptoms and fatty liver disease in later life (86, 122). Mutations 230 
of the gene coding for the brain-specific paralog AGC1 (SLC25A12) lead to early infantile 231 
epileptic encephalopathy due to hypomyelination (OMIM 603667). This is caused by the lack 232 
of mitochondrial aspartate export, which is required for the synthesis of N-acetyl-aspartate, 233 
a precursor for myelin synthesis (167). 234 
Two related proteins, the mitochondrial glutamate carriers GC1 (SLC25A22) and GC2 235 
(SLC25A18), are involved in the import of glutamate together with a proton, but do not 236 
export aspartate (FIGURE 1D) (50). The glutamate carriers do not have the calcium-237 
regulatory elements found in aspartate/glutamate carriers. Mutations in SLC25A22 (OMIM 238 
609302) cause neonatal epileptic encephalopathy with suppression bursts (97, 110), or 239 
migrating partial seizures in infancy with poor developmental prognosis (129). The most 240 
likely reason for the disease phenotype is the role of mitochondrial glutamate transport in 241 
sustaining glutamate homeostasis in astrocytes (55). 242 
The glycine carrier GLYC (SLC25A38) is involved in the import of glycine into 243 
mitochondria, where it reacts enzymatically with succinyl-CoA to form aminolevulinic acid 244 
(FIGURE 1G) (102). The gene was flagged up because a disease variant leads to autosomal 245 
recessive sideroblastic anemia (OMIM 610819), caused by the inability of blood cells to 246 
synthesize heme due to defective glycine transport (48). Aminolevulinic acid is transported 247 
by an unknown transporter into the cytosol, where it is used as a precursor for porphyrin 248 
synthesis. The resulting coproporphyrinogen III is then transported into mitochondria by an 249 
unknown transporter for incorporation of iron and insertion into heme-containing proteins. 250 
The ornithine carriers ORC1 and ORC2 (SLC25A15 and SLC25A2) catalyze the 251 
exchange of ornithine and citrulline, which links the fixation of ammonia in mitochondria to 252 
the urea cycle (FIGURE1H) (47). The substrate specificity and binding of these two paralogs 253 
have been studied in detail (111). Dysfunction of ORC1 (SLC25A15) leads to HHH syndrome 254 
(OMIM 603861), characterized by hyperornithinemia, hyperammonemia and 255 
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homocitrullinuria, due to an impaired urea cycle, which is required for the deamination of 256 
amino acids (22, 65). ORC2 (SLC25A2) (OMIM 608157) may be responsible for the milder 257 
phenotype in HHH patients, secondary to a gene redundancy effect. The basic amino acid 258 
carrier BAC (SLC25A29) is closely related to ORC1 and 2, but transports arginine, lysine, 259 
homoarginine, methylarginine and, to a much lesser extent, ornithine and histidine (131) 260 
and has thus far no pathology associated with it. 261 
 Recently, the mitochondrial carrier for branched-chain amino acids (SLC25A44) was 262 
identified (FIGURE 1D) (171). The branched-chain amino acids valine, leucine and isoleucine 263 
can be degraded to provide metabolic energy and are required for the synthesis of proteins 264 
in mitochondria. The carrier was discovered in brown adipose tissue upon cold exposure, 265 
where branched-chain amino acids can be used as a fuel for thermogenesis. 266 
 267 
Vitamin transport 268 
Many vitamins need to be transported into mitochondria, where they serve as co-factors or 269 
as donors of key functional groups in the enzymatic reactions of the mitochondrial matrix 270 
(FIGURE1I). 271 
The mitochondrial S-adenosylmethionine carrier SAMC (SLC25A26) imports S-272 
adenosylmethionine into mitochondria, which is required for methylation reactions of DNA, 273 
RNA and protein in the mitochondrial matrix, and exports the product S-274 
adenosylhomocysteine (3). A missense mutation in the gene coding for this protein causes 275 
intra-mitochondrial methylation deficiency (OMIM 611037) in agreement with this function, 276 
leading to oxidative phosphorylation deficiency (82). 277 
The human thiamine pyrophosphate transporter TPC (SLC25A19) was initially 278 
identified as a deoxynucleotide transporter (39), but its main function is the transport of 279 
thiamine pyrophosphate, which is an important co-factor in dehydrogenase reactions (99). 280 
Defective transport of thiamine pyrophosphate is the cause of Amish microcephaly, which is 281 
characterized by profound congenital microcephaly, delayed psychomotor development, 282 
lactic and alpha-ketoglutaric aciduria (OMIM 606521) (78). A second mutation was reported 283 
in siblings of non-Amish background (OMIM 613710), expanding the phenotypes associated 284 
with the SLC25A19 gene. These patients showed recurrent episodes of flaccid paralysis and 285 
encephalopathy associated with bilateral striatal necrosis and chronic progressive 286 
polyneuropathy caused by a missense mutation in SLC25A19 (155). 287 
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Mitochondria require folate for one-carbon metabolism and flavins for electron 288 
transfer steps in the respiratory chain. The transport of folate and flavin have both been 289 
assigned to a single mitochondrial carrier (SLC25A32) (154, 159). The substrate binding site 290 
has typical features of an adenine binding pocket, agreeing with the flavin assignment (94, 291 
136, 137). When mutated, the disease variant of this carrier causes exercise intolerance 292 
(OMIM 610815) and riboflavin supplementation proved to be beneficial to the patients, 293 
indicating that the most likely substrate of this carrier is flavin rather than folate (149). 294 
Many reactions in the mitochondrial matrix, such as dehydrogenase activities, 295 
require coenzyme A (CoA) as co-factor. Coenzyme A is synthesized outside of mitochondria 296 
and must be transported into the mitochondrial matrix. The CoA transporter (SLC25A42) was 297 
initially identified based on database searches and showed expression in all tissues with the 298 
highest levels detected in adipose tissue, and high levels detected in hypothalamus and all 299 
brain coronal sections (57). The disease variant of the CoA transporter (OMIM 610823) 300 
causes mitochondrial myopathy with muscle weakness and lactic acidosis, while other 301 
tissues and cognitive functions are not impaired (150). Another report described variable 302 
clinical manifestations, including lactic acidosis, developmental regression and epilepsy (4). 303 
Before SLC25A42 was identified as the CoA transporter, this transport activity was 304 
putatively assigned to protein encoded by the SLC25A16 gene (133). Both SLC25A16 and 305 
SLC25A42 are phylogenetically related to the yeast protein Leu5p and are capable of 306 
complementing the yeast knockout strain (51). The function and kinetic parameters of 307 
SLC25A42 were determined in transport assays with substrate specificities restricted to CoA, 308 
dephospho-CoA, ADP, and adenine-3’,5’-diphosphate (51). The human protein encoded by 309 
the SLC25A16 gene has been identified through a possible association with a thyroid disease 310 
called Grave’s disease, but it has not been demonstrated that it can transport CoA (173). To 311 
date only a single homozygous mutation has been reported in the SLC25A16 gene (OMIM 312 
139080) causing a nail disorder of the hand with different severity levels of onychodystrophy 313 
(79), but a direct correlation to function has not been confirmed either. 314 
 315 
Inorganic ion transport 316 
Inorganic ions also need to be transported into the mitochondrial matrix, where they 317 
function as co-factors, as substrates for enzymatic reactions and as regulators. There are 318 
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likely to be transporters of other families as well as channels involved in inorganic ion 319 
transport, but they are beyond the scope of this review. 320 
The mitoferrins SLC25A37 (MFRN1) and SLC25A28 (MFRN2) have been proposed to 321 
transport iron ions into mitochondria for incorporation into heme and iron-sulfur cluster 322 
synthesis, as well as other functions (FIGURE 1J) (113, 151). MFRN1 is highly expressed in 323 
differentiating erythroid cells and in other tissues at low levels, while MFRN2 is expressed 324 
ubiquitously in non-erythroid tissues (29, 151). Abnormal MFRN1 expression might 325 
contribute to erythropoietic protoporphyria phenotype in agreement with this notion (165).  326 
The mitochondrial phosphate carrier PIC (SLC25A3) imports inorganic phosphate for 327 
the synthesis of ATP (140) together with a proton (FIGURE 1K) (95). There are two 328 
alternative splicing variants showing different kinetic parameters and different expression 329 
profiles: while isoform A is highly expressed in heart, skeletal muscle, diaphragm (49), and 330 
pancreas (67), isoform B is expressed in all tested tissues, i.e., lung, kidney, brain, thymus, 331 
liver, heart, skeletal muscle, and diaphragm (49), albeit at lower levels compared to isoform 332 
A (67). The phosphate carrier is fundamental in maintaining the inorganic phosphate pool in 333 
the mitochondrial matrix, but there are also other carriers capable of transporting 334 
phosphate, such as the dicarboxylate carrier DIC (SLC25A10) and mitochondrial ATP-Mg/Pi 335 
carriers APC1 (SLC25A24), APC2 (SLC25A23), APC3 (SLC25A25), and APC4 (SLC25A41) (5, 45, 336 
160). Phosphate carrier deficiency leads to lactic acidosis, hypertrophic cardiomyopathy, and 337 
muscular hypotonia and early mortality (OMIM 600370) in agreement with the notion that 338 
its transport activity is the main pathway for phosphate import for ATP synthesis (15, 105, 339 
106). 340 
 341 
Fatty acid transport 342 
The carnitine/acylcarnitine carrier CAC (SLC25A20) is a key component of the carnitine cycle 343 
and imports acyl-carnitine into mitochondria for fatty acid β-oxidation and exports carnitine 344 
(FIGURE1L) (66, 70). Mutations cause carnitine/acylcarnitine carrier deficiency, an autosomal 345 
recessive disorder characterized by severe, neonatal onset with cardiomyopathy or a milder 346 
phenotype with hypoglycemia, but no cardiomyopathy (OMIM 613698) (66). The inability to 347 
transport fatty acid chains into mitochondria makes the patients dependent on 348 
carbohydrates and amino acids for energy metabolism. 349 
 350 
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Uncoupling protein 351 
The uncoupling protein UCP1 (SLC25A7) is predominantly found in brown adipose tissue of 352 
neonatal mammals (6, 118, 120), but is also found in the supraclavicular and the neck 353 
regions in adults in later life (FIGURE 1M) (116). UCP1 dissipates the proton motive force, 354 
short-circuiting the mitochondrion, which leads to the production of heat. The generation of 355 
heat from the oxidation of brown adipose fat protects the newly born against cold stress of 356 
vital organs. UCP1 is activated by fatty acids and inhibited by purine nucleotides (134), but 357 
the mechanism is still debated (23, 33, 44, 72, 84, 119). UCP1 is monomeric and binds three 358 
cardiolipin and a single purine nucleotide (96). Based on sequence analysis, UCP1 has 359 
retained all of the key features of mitochondrial carriers, indicating that it operates by a 360 
conventional carrier-like mechanism (33, 96). The transport of protons induced by fatty acids 361 
is relatively slow (44), which would fit a transporter rather than a channel mechanism, but a 362 
molecular mechanism has not been resolved. Although there are other closely related 363 
proteins (see below), UCP1 is most likely the only one involved in thermogenesis. There are 364 
no known disease states associated with mutations in the gene coding for UCP1. 365 
 366 
Dicarboxylate transport 367 
Dicarboxylates (FIGURE 1N) need to be continuously exchanged across the mitochondrial 368 
inner membrane for many different pathways, such as the tricarboxylic acid cycle, 369 
malate/aspartate shuttle, gluconeogenesis, and amino acid metabolism. 370 
The mitochondrial dicarboxylate carrier DIC (SLC25A10) is involved in the transport of 371 
malonate, malate, succinate, sulphate, thiosulphate, and phosphate by electroneutral 372 
exchange (46, 73). The carrier is involved in gluconeogenesis and ureogenesis, the 373 
metabolism of sulfur compounds, as well as in de novo fatty acid synthesis (109). The 374 
mitochondrial oxoglutarate carrier OGC (SLC25A11) exchanges cytosolic malate for 2-375 
oxoglutarate from the mitochondrial matrix and plays an important role in the malate-376 
aspartate shuttle, the oxoglutarate-isocitrate shuttle, and gluconeogenesis (69). Mutations 377 
in the gene might be correlated to metastatic paragangliomas (21). 378 
The oxodicarboxylate carrier ODC (SLC25A21) import 2-oxoadipate and exports 2-379 
oxoglutarate, playing a central role in the catabolism of lysine, hydroxylysine and tryptophan 380 
(FIGURE 1O) (48). Oxodicarboxylate carrier deficiency (OMIM 607571) is associated with 381 
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mitochondrial DNA depletion and spinal muscular atrophy-like disease, most likely caused by 382 
the accumulation of toxic amino acid breakdown products (17). 383 
There are several closely related sequences to UCP1, such as UCP2 (SLC25A8), UCP3 384 
(SLC25A9), UCP4 (SLC25A27), UCP5 (SLC25A14), and UCP6 (SLC2530), but they are likely to 385 
be transporters of carboxylic acids (54, 163), which is in agreement with their close 386 
phylogenetic relationship to dicarboxylate transporters (123) and with the properties of 387 
their substrate binding sites (137). Many unresolved questions remain with respect to their 388 
molecular properties and their role in thermogenesis and metabolism. There are also other 389 
potential dicarboxylate carriers, such as SLC25A34 and SLC25A35, but their role in 390 
metabolism has not been clarified. 391 
 392 
Tricarboxylate transport 393 
The tricarboxylate or citrate carrier (SLC25A1) catalyzes the electroneutral exchange of 394 
tricarboxylates (citrate, isocitrate) for another tricarboxylate, a dicarboxylate or 395 
phosphoenolpyruvate (68, 76, 103). An important physiological function is the export of 396 
citrate from the mitochondria to the cytosol for the production of acetyl CoA, which is a 397 
starting point for lipid, dolichol, ubiquinone and sterol synthesis (references in (103)), and 398 
acetylation reactions (112) (FIGURE 1P). Citrate carrier deficiency (OMIM 190315), which is 399 
hallmarked by combined D-2- and L-2-hydroxyglutaric aciduria, leads to neonatal-onset 400 
epileptic encephalopathy with severe muscular weakness, respiratory distress, and lack of 401 
psychomotor development resulting in early death (30, 42, 114, 121, 132, 152), which is 402 
most likely due to the severe biosynthetic deficiencies (103). Many of the missense 403 




SLC25A50 (MTCH2) is a partially characterized mitochondrial carrier, which acts as a 408 
receptor-like protein for the truncated BH3-interacting domain death agonist protein in the 409 
outer membrane of mitochondria, as part of the apoptosis pathway (FIGURE 1Q) (172). 410 
MTCH2 is likely to have a similar topology as other mitochondrial carriers (135), but 411 
unusually it is found in the mitochondrial outer membrane. A transported substrate has not 412 
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yet been identified, if this protein has a transporter function at all, but MTCH2 was 413 
subsequently found to be required and sufficient for lipid homeostasis shifts (139). 414 
 415 
Mitochondrial dynamics 416 
The partially characterized mitochondrial carrier SLC25A46 is most likely involved in 417 
mitochondrial dynamics (FIGURE 1R). Overexpression leads to mitochondrial fragmentation, 418 
whereas knockdown results in hyperfilamentous mitochondria and mitochondrial 419 
hyperfusion, likely resulting from decreased fission. Loss of SLC25A46 was not associated 420 
with changes in total ATP concentration, mitochondrial DNA content, or membrane 421 
potential (2). SLC25A46 could interact with proteins associated with mitochondrial 422 
dynamics, such as OPA1 and MFN2, and with components of the mitochondrial contact site 423 
and mitochondrial cristae organizing system complex, which plays a role in cristae 424 
maintenance (71). SLC25A46 might also interact with components of an endoplasmic 425 
reticulum membrane protein complex involved in lipid transfer to mitochondria, which are 426 
also required for cristae growth and maintenance. SLC25A46 is found in the outer 427 
membrane of mitochondria (71), which is atypical for mitochondrial carriers except for 428 
MTCH2 (see above). It is possible that the carrier has evolved away from the canonical 429 
transporter function, as, so far, no substrates have been identified. Disease variants of 430 
SLC25A46 (OMIM 610826) lead to hereditary motor and sensory neuropathy type VIB (2) 431 
and in severe cases to death in infancy (1, 164). 432 
 433 
Uncharacterized mitochondrial carriers 434 
The functions of a large number of mitochondrial carriers have not yet been assigned, 435 
limiting our understanding of their role in human physiology and pathology. Among them 436 
are SLC25A34, SLC25A35, SLC25A39, SLC25A40, SLC25A43, SLC25A45, SLC25A47, SLC25A48, 437 
SLC25A49 (MTCH1), SLC25A51 (MCART1), SLC25A52 (MCART2) and SLC25A53 (MCART6), 438 
which is roughly a quarter of the total. No substrates have been identified for SLC25A46 and 439 
SLC25A50 (MTCH2) (see above), although they have a role in mitochondrial dynamics and 440 
apoptosis, respectively. There is still a lot of debate on the role of UCP2 (SLC25A8), UCP3 441 
(SLC25A9), UCP4 (SLC25A27), UCP5 (SLC25A14), and UCP6 (SLC2530) in human physiology. In 442 
some other cases, the function of particular carriers has been disputed, for example 443 
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SLC25A32, which has been described as a folate or flavin transporter. Counting these, the 444 
number of carriers that are not yet fully characterized is closer to a third of the total. 445 
 446 
The molecular basis of pathogenic missense mutations 447 
Missense mutations in 16 different carriers lead to human disease, but it is likely that this 448 
number will increase substantially as more links are discovered through genome and exome 449 
sequencing. These mutations can impair the structure and mechanism of the carrier, but can 450 
also cause issues with biogenesis, i.e. the expression, targeting, insertion and folding of the 451 
disease variant. The impact of the vast majority of these missense mutations on the 452 
structure, function and biogenesis of the carrier has not been studied experimentally. To 453 
discriminate between these different scenarios, it is important to understand the transport 454 
mechanism in detail. Recently, good progress has been made facilitating this assessment, 455 
although many details still need to be worked out. To explain the molecular impact of the 456 
pathogenic mutations on the function of mitochondrial carriers, it is important to explain 457 
their basic structure and transport mechanism first. 458 
 459 
Structures of mitochondrial carriers 460 
Mitochondrial carriers consist of three homologues repeats of about one hundred amino 461 
acid residues each (FIGURE 3A) (147). The three repeats fold up into a three-fold pseudo-462 
symmetrical fold, noted first in the projection structure of the yeast ADP/ATP carrier Aac3p 463 
(92). This study also demonstrated that the carrier had a monomeric structure and a 464 
translocation path for substrates through the center of the protein (92). The first atomic 465 
structure of the bovine ADP/ATP carrier provided the first evidence for the basic structural 466 
topology of all mitochondrial carriers (128). Each repeat or domain has an odd-numbered 467 
helix (H1, H3, H5), a matrix loop of variable length, a matrix helix (h12, h34, h56), a linker 468 
helix (l12, l34, l56), and an even-numbered helix (H2, H4, H6) (128) (FIGURE 3A and B). The 469 
domains are linked by cytoplasmic loops, which are located in the intermembrane space, 470 
together with the N- and C-termini. The structure was locked by the specific inhibitor 471 
carboxyatractyloside in the cytoplasmic state in which the central cavity is open to the 472 
intermembrane space and via channels to the cytoplasm, for binding of ADP (FIGURE 4) 473 
(128). Although there are some structural differences, the same basic structural fold was 474 
observed for the yeast ADP/ATP carrier Aac2p and Aac3p, even though they share only ~50% 475 
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identity with the bovine carrier (141). More recently, the atomic structure of the 476 
mitochondrial ADP/ATP carrier inhibited by bongkrekic acid was solved, locked in the matrix 477 
state in which the central cavity is open to the mitochondrial matrix, for binding of ATP 478 
(FIGURE 4) (142, 144). The central cavity in both states is positively charged, primed for 479 
binding of the negatively charged adenine nucleotides (128, 142, 144). The residues of the 480 
substrate binding site have been identified by computational methods, using chemical and 481 
distance constraints in comparative models (94, 136), deviation of symmetry (95, 137), or 482 
molecular dynamics simulations (35, 107, 166). The three main contact points involved in 483 
substrate binding are located on the even-numbered helices (FIGURE 4) (94, 136). The 484 
substrate binding site is located at the bottom of a water-filled cavity in both states, which 485 
corresponds to the middle of the membrane (94, 136). There are two gates on either side of 486 
the carrier that regulate access to the central binding site. In the cytoplasmic state, the 487 
matrix gate is closed and the cytoplasmic gate is open, whereas in the matrix state, the 488 
cytoplasmic gate is closed and the matrix gate is open (FIGURE 4) (142-144). Each closed 489 
gate is about 15-Å thick, an important insulation layer to prevent the leak of protons and 490 
other ions in the presence of a 180-mV membrane potential. These gates contain salt bridge 491 
networks of positively and negatively charged amino acid residues and other features, which 492 
will be discussed later. 493 
 494 
Transport mechanism of mitochondrial carriers 495 
Comparison of the two inhibited states has revealed the basic structural mechanism of 496 
transport and has completed our understanding of the importance of key conserved 497 
sequence features of the SLC25 family for the transport mechanism (FIGURE 5) (142-144). 498 
The two inhibitors occupy the proposed substrate binding site of the carrier, preventing 499 
substrate binding, but also induce slight conformational changes, which lock the carrier 500 
permanently in an abortive state (142). These distortions can be corrected for structurally to 501 
achieve a closer approximation of the unliganded states, which are used in this review. A 502 
morph between the unliganded states passes through an occluded state, where access to 503 
the substrate binding site is blocked from both sides of the membrane, which is a 504 
requirement for an alternating access transport mechanism (142). 505 
Further analysis shows that most of the domain structure is conserved between the 506 
two states, i.e. the odd-numbered helix, the matrix helix, the linker helix and a third of the 507 
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even-numbered helix (142-144). These parts of the domain are called the core elements, and 508 
are shown in primary colors, blue, yellow and red for the first, second and third domain, 509 
respectively (FIGURE 5). In contrast, a significant change occurs in the position of the C-510 
terminal regions of the even-numbered helices in the state interconversion (143, 144). These 511 
parts of the structure are called the gate elements, and they are shown in gray (FIGURE 5). 512 
The hinge points of these movements turned out to be the contact points of the proposed 513 
substrate binding site (142-144), identified previously (94, 136). Opening or closing of the 514 
matrix side of the carrier involves the rotation of the three core elements as rigid-bodies, 515 
whereas opening or closing of the cytoplasmic side requires the rotation of three gate 516 
elements. In this way, access to the central substrate binding site from one or the other side 517 
of the membrane is alternated (FIGURE 5). The substrate binding site is the fulcrum of these 518 
movements (142-144). Thus, state interconversion requires the coordinated movement of 519 
six elements simultaneously, making the mitochondrial carriers one of the most dynamic of 520 
all transport proteins. These movements are facilitated by the transmembrane helices being 521 
held together only by relatively weak van der Waals interactions. Next, the sequence 522 
features of mitochondrial carriers are examined to determine why they are crucial to the 523 
structure and transport mechanism, as they are often altered in pathogenic variants.  524 
 525 
Key sequence features affected by pathogenic mutations 526 
The easiest way to present the sequence features of mitochondrial carriers is to use their 527 
three-fold pseudo-symmetry (FIGURE 3). The three repeats are homologous to each other, 528 
meaning that residues that are in the same position in each repeat are symmetry-related 529 
and thus mostly identical or similar in physiochemical properties (137). These residues can 530 
be grouped together in a triplet of symmetry-related residues, which facilitates their 531 
comparison (FIGURE 3A). Here, we have used the residue numbering of the human ADP/ATP 532 
carrier 1 (AAC1, SLC25A4), also known as ANT1, to relate the triplet to the original sequence. 533 
For example, the highlighted triplet (cyan sphere) in FIGURE 3A contains residue 8 in repeat 534 
1, residue 113 in repeat 2, and residue 210 in repeat 3 (FIGURE 3). For convenience, the 535 
entire triplet is named by the residue number in the first repeat in SLC25A4, meaning that 536 
the example above would be called triplet 8. Given the high sequence identity within the 537 
SLC25 family, the same triplets in carriers with different functions can be compared to look 538 
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for ones that are conserved throughout the family, and are therefore universally important 539 
for the structure and mechanism of mitochondrial carriers (137). 540 
FIGURE 6 shows the triplets of all conserved helical features for the 16 mitochondrial 541 
carriers that have been linked to human disease, as well as the reported pathogenic 542 
mutations. The mutations that have been experimentally verified to have a severe effect on 543 
function are shown in red boxes, whereas those that have milder effects are in yellow ones. 544 
Mutations shown in blue boxes have been flagged up in genetic analysis, but their effect on 545 
function has not been studied experimentally. It is clear that mutations affect a large 546 
number of triplets. Next, starting from the N-terminus, these features will be presented by 547 
highlighting the properties of the triplets in relation to the known structural mechanism of 548 
transport (FIGURE 6). The analysis focusses on the conserved helical parts of the carriers, as 549 
the loops are highly variable in length and sequence, and do not play an important role in 550 
the transport mechanism. The most conserved amino acid residues of the triplets are 551 
indicated by the one-letter amino acid code, whereas the most common chemical and 552 
physical properties are also indicated by a one-letter code: π for small residues (Gly, Ala, Ser, 553 
Pro, Cys, Val, Thr), Φ for hydrophobic residues (Val, Ile, Leu, Phe, Trp, Tyr, Cys, Ala, and Met), 554 
Ω for aromatic residues (Trp, Tyr, Phe) and ξ for hydrophilic residues (Asn, Gln, Glu, Asp, Lys, 555 
Arg, His, Ser, Thr) , and X for any residues. 556 
 557 
Small amino acid residues on the odd-numbered helices 558 
The odd-numbered helices H1, H3 and H5 have a strong kink, giving them an L-shape 559 
(FIGURE 3 and 4) (128). The N-terminal parts are transmembrane and contain a large 560 
number of glycine and other small residues, which are often mutated in disease variants of 561 
the carriers (FIGURE 6). The extended sequence motif is πGπxπGxxπxxxπ, where G stands for 562 
glycine and π for small amino acids and x for any amino acid residue (142-144) (FIGURE 7). 563 
These residues can be divided further into two categories: (i) Small residues in the interface 564 
with the preceding helix, i.e. triplets 14, 18, 22, and 26 (pink residues, FIGURE 7), and (ii) 565 
glycine or small residues in the interface with the following helix, i.e. triplets 15 and 19, 566 
which form the GxxxG motif, and triplet 16 (magenta residues, FIGURE 7) (141-144).  567 
When the carrier transitions from the cytoplasmic state to the matrix state (FIGURE 4 568 
and 5), the cytoplasmic side of the carrier closes and the transmembrane helices come 569 
together. The reason is that the cytoplasmic side closes because the gate elements rotate 570 
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inwards, allowing the cytoplasmic network to form (see below). At the same time, the core 571 
elements rotate outwards, and simultaneously the odd helices move inwards on the 572 
cytoplasmic side. The glycine and other small residues of the πGπxπGxxπxxxπ motif are in 573 
these crucial interhelical interfaces, allowing movement of the gate elements across the 574 
surface of the odd-numbered helices and the close proximity of the helices in the matrix 575 
state. A large number of pathogenic mutations are observed in these triplets, and functional 576 
and structural analysis shows that these residues are likely to be important for the 577 
mechanism of mitochondrial carriers in general (25, 33, 90). Small residues can also be found 578 
on the even-numbered helices, as will be discussed below. 579 
The other triplets found on the transmembrane parts of the odd-numbered helices 580 
preserve their strong amphipathic properties. Triplets 8, 9, 10, 12, 13, 17, 20, 21, 24, and 25 581 
contain mostly generic hydrophobic residues (Φ symbols, FIGURE 6), as they point towards 582 
the hydrophobic core of the membrane. Triplets 11, 23, and 27 contain generic hydrophilic 583 
residues (ξ symbols, FIGURE 6) and point towards the water-filled cavity. Pathogenic 584 
mutations are sporadically observed in these triplets, most likely when they are replaced 585 
with a residue with the opposite properties. For instance, a charged residue for a 586 
hydrophobic one, a large residue for a small one, or a substitution with a proline residue in 587 
the middle of a helix, which could break the helix. These features could be important for 588 
both the function and biogenesis of the carriers. 589 
 590 
Key amino acid residues of the matrix gate 591 
The next important motif on the odd-numbered helices is a highly conserved symmetrical 592 
feature Px[DE]xx[RK]xxxQ (FIGURE 6). As mentioned above, the odd-numbered helices have 593 
a strong kink of about 50 degrees (FIGURE 5). At this kink is a highly conserved proline 594 
residue (P-kink, triplet 28), the first residue of the motif (128), but it can be replaced by a 595 
serine residue (141). These residues break the hydrogen bond arrangement allowing the 596 
kink to occur and a network of interactions between residues in the domain help to stabilize 597 
it (141) (FIGURE 8). The kinks bring the C-terminal ends of the odd-numbered helices 598 
together in the center of carrier in the cytoplasmic state, where the negatively charged 599 
residues (red residues. triplet 30) and positively charged residues (blue residues, triplet 33) 600 
form an ionic interaction network (117). This interaction network can be seen in the 601 
structure of the cytoplasmic state (128, 141), now called the matrix salt bridge network 602 
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(137). A glutamine residue (triplet 37) functions as a brace of one of the salt bridge 603 
interactions of the matrix network (glutamine-brace) (green residue, FIGURE 8) (141). Only 604 
one of the three domains of the ADP/ATP carrier has a glutamine brace, but other carriers 605 
have up to three glutamine braces (FIGURE 6). The salt bridge interactions and glutamine 606 
braces together determine the overall interaction energy of the matrix network. Although 607 
not conserved between different carriers, residues in triplet 34 and 38 are in the 608 
translocation path, sealing the carrier to the mitochondrial matrix (FIGURE 6). Together, all 609 
these residues form the matrix gate, which is closed in the cytoplasmic state and open in the 610 
matrix state (FIGURE 5 and 6). In addition, there are triplets with hydrophobic residues 611 
(triplet 29, 32, 36), hydrophilic residues (triplet 34, 38), and residues with varied properties 612 
(triplet 31). This part of the carrier is one of the most important for their function and a large 613 
number of pathogenic variants have been identified in this region (FIGURE 6). 614 
 615 
Amino acid residues involved in cardiolipin binding 616 
Three cardiolipin molecules are tightly bound to mitochondrial carriers and are important for 617 
their stability and function, as observed by phosphorous NMR experiments (14), 618 
crystallographic analyses (128, 141, 142), lipid analysis (10, 93, 96), disease models (56, 74, 619 
104), thermostability analysis (34), and transport assays (63, 75, 107). The phosphate groups 620 
of cardiolipin are bonded to the N-terminal ends of the matrix and even-numbered helices, 621 
bridging the inter-domain interface (FIGURE 9). Preceding them are highly conserved 622 
symmetrical sequence motifs [YF]XG (triplets 51-53, cardiolipin binding site I) and 623 
[YWF][RK]G (triplets 71-73, cardiolipin binding site II), respectively (FIGURE 6 and 10). The 624 
glycine residues of these motifs (triplets 53 and 73) are in the loop to helix transition, where 625 
they function as helix breakers, but serine, asparagine or threonine can also play this role 626 
(24). This loop to helix transition is crucial for binding of the phosphate groups of cardiolipin 627 
via hydrogen bonds (128) and electrostatic interactions with the helix dipoles (141). Many 628 
pathogenic mutations affect these glycine residues (FIGURE 6). The aromatic residue of 629 
cardiolipin binding site I (triplet 51) is involved in stabilization of the domain on the matrix 630 
side (108), whereas the aromatic residue of cardiolipin binding site II (triplet 71) is involved 631 
in binding the fork of the lipid moiety (128, 141, 142). Although not supported by the 632 
structures, molecular dynamics simulations show that the positive charged residue (triplet 633 
72) might be involved in binding the phosphate moiety via electrostatic interactions (41). 634 
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Triplet 71-72 have pathogenic mutations, supporting their importance in stability and 635 
function of the carriers. 636 
 637 
Amino acid residues important for the stability of the domain structure  638 
Analysis of all of the polar interactions of the ADP/ATP carrier show that there are no 639 
conserved polar interactions between the transmembrane helices (141), which agrees with a 640 
mechanism where the transmembrane helices move relative to each other in the state 641 
interconversion (FIGURE 5)(142). The only highly conserved interaction is in the domain 642 
structure between a positively charged residue on the odd-numbered helices (E-R link I, 643 
triplet 35) and a negatively charged residue on the matrix helices (E-R link II, triplet 65) 644 
(FIGURE 6 and 11). In the known structures of the ADP/ATP carrier one or two interactions 645 
are evident, supporting the unusual shape of the domain structure (128, 141, 142). One of 646 
the residues of E-R link I in repeat I is a leucine, which cannot be involved in a direct 647 
interaction with the glutamine residue in E-R link II (FIGURE 6). However, a preceding residue 648 
Arg31, which is located one turn of a helix away, is in bonding distance, thus fulfilling the 649 
same role (FIGURE 6). On the basis of sequence analysis, it is likely that all three domains 650 
have this interaction in other carriers, which it has been shown to be important for function 651 
(108). 652 
 Another residue important for the stability is a tyrosine residue in cardiolipin binding 653 
site I (triplet 51), which forms extra interactions and seals the domain towards the 654 
mitochondrial matrix (FIGURE 10). The E-R link often contains pathogenic mutations, further 655 
supporting its importance. 656 
Residues of the matrix helices are strongly amphipathic with polar and charged 657 
residues facing the mitochondrial matrix (triplets 56, 59, 60, 63, 64) and hydrophobic 658 
residues facing the membrane (triplets 54, 55, 58, 61, 62) (FIGURE 6). Small residues are also 659 
required for the stability of the domain structure, as helix breakers, such as glycine residues 660 
(triplet 53, 66, 73), or small residues pointing towards other residues (triplet 57, 69) (FIGURE 661 
11). These areas are affected by pathogenic mutations, likely because the mutations cause 662 
changes to amino acids with opposite biophysical properties. 663 
 664 
Amino acid residues of the substrate binding site  665 
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A single substrate binding site can be found in the central cavity, approximately halfway the 666 
membrane. The binding site consists of residues that are directly involved in binding of the 667 
substrate, such as the contact points (FIGURE 4, 5 and 12), but also of residues that allow the 668 
binding of the substrate in the water-filled cavity. This area is a hyper-variable region and 669 
contains a large number of asymmetric residues (137). Most of these residues can be found 670 
on the even-numbered helices at triplets 77, 80 (contact points), 81, 84, and possibly 85. 671 
There are many disease variants that have mutations in this area, and which have been 672 
shown to affect function in functional studies. There are also triplets that often contain 673 
proline residues, such as triplet 76 and 83, which can be found on either side of the contact 674 
points (triplet 80) and may facilitate the curvature or the relative movement of the helices. 675 
 676 
Small amino acid residues on the even-numbered helices 677 
As explained earlier, the state interconversion requires the presence of small residues in the 678 
interhelical interfaces. Several can be found on the even-numbered helices that facilitate 679 
these movements, such as the aforementioned triplet 76, and a πxxxπ motif, formed by 680 
triplet 86 and 90 (FIGURE 6 and 13). The even-numbered helices are also highly amphipathic, 681 
containing hydrophobic residues in triplets 74, 75, 78, 79, 82, 87, and 91, facing the 682 
membrane, and hydrophilic residues facing the cavity, such as the substrate binding site 683 
residues, and triplets 88, 94 and 97 (FIGURE 6). 684 
 685 
Amino acid residues of the cytoplasmic gate  686 
The C-terminal ends of the even-numbered helices contain highly conserved symmetrical 687 
sequence motifs ξ[FY]xx[YF][DE]xx[RK] (triplets 88-96). Together, they form the cytoplasmic 688 
gate (FIGURE 6). The negative charged residues (triplet 93) and positively charged residues 689 
(triplet 96) form the cytoplasmic salt bridge network, when the carrier is in the matrix state 690 
(80, 142, 144), whereas this network is disrupted in the cytoplasmic state (red and blue 691 
residues, FIGURE 14) (141). The preceding aromatic residue (triplet 92), most often a 692 
tyrosine residue, can form hydrogen bond interactions with the negative charged residue of 693 
the neighboring domain (orange residue, FIGURE 14). This interaction is called the tyrosine 694 
brace, and mitochondrial carriers have one to three of these interactions, modifying the 695 
overall interaction energy of this network. Together with triplet 89, it also doubles up as a 696 
hydrophobic layer when the carrier is in the matrix state. Triplet 88, which is quite variable, 697 
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is part of the cytoplasmic gate and also forms part of the ceiling of the substrate binding site 698 
(green residues, FIGURE 14). These residues are often mutated in disease variants. 699 
 700 
Concluding remarks 701 
Mitochondrial carriers are highly dynamic transporters, which interconvert between a 702 
cytoplasmic state and a matrix state using six dynamic elements, comprising three core 703 
elements and three gate elements. They are among the smallest transporters in nature, yet 704 
they transport some of the largest molecules, such as adenine nucleotides, S-adenosyl 705 
methionine, flavins and acyl-carnitines. They do so without significant proton leak, because 706 
of a matrix and cytoplasmic gate, both with salt bridge networks and braces, and other 707 
residues that provide an insulation layer. All carriers have a single central substrate binding 708 
site with three contact points, which is alternately accessible from one side of the 709 
membrane or the other, key properties of an alternating access transport mechanism. A 710 
large number of pathogenic mutations have been identified, which cause a range of 711 
metabolic, neuromuscular and developmental diseases. The vast majority of them can be 712 
explained because they affect key structural and functional features of mitochondrial 713 
carriers. Some of them are found in loop regions, which have not been included in this 714 
analysis, and others in extra domains, such as the regulatory domain of the 715 
aspartate/glutamate carrier, which have been explained before (FIGURE 2C) (157). The few 716 
that are remaining, often involve mutations that introduce different properties from those 717 
of the original residue (e.g. p.Asp69Tyr in SLC25A1, p.Cys23Arg in SLC25A20, or p.Thr56Pro 718 
in SLC25A22), which could impair the structure and function, but also the biogenesis of the 719 
carrier. To understand these diseases, it is really important to discriminate between these 720 
different options, but the majority of these pathogenic mutations have not been studied 721 
experimentally. Given the fact that so many amino acid residues are important for the 722 
function of mitochondrial carriers, and that the SLC25 family is the largest solute carrier 723 
family in humans, it is likely that many more disease variants will be discovered. 724 
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Legends to the figures 1356 
 1357 
FIGURE 1. The role of the human mitochondrial carrier family (SLC25) in metabolism and 1358 
mitochondrial function 1359 
Schematic representation of the mammalian mitochondrion. Shown in green are the 1360 
electron transfer chain complexes, bottom to top; glycerophosphate dehydrogenase, fatty 1361 
acid-dehydrogenase-electron transfer flavoprotein, dihydroorotate dehydrogenase, and 1362 
complex I to IV with cytochrome c. Shown in blue is the dimer of ATP synthase and in 1363 
red/orange the mitochondrial pyruvate carrier heterodimer (MPC). Shown in purple and 1364 
yellow are unidentified and identified mitochondrial carriers, respectively: AAC1-4, ADP/ATP 1365 
carriers; AGC1-2, aspartate/glutamate carriers; APC1-4, ATP-Mg/Pi carriers; BAC, basic 1366 
amino acid carrier; CAC, carnitine-acylcarnitine carrier; CIC, citrate carrier; DIC, dicarboxylate 1367 
carrier; GC1-2, glutamate carriers; GLYC, glycine carrier; MTFRN1-2 mitoferrins; ODC, 1368 
oxoadipate carrier; OGC, oxoglutarate carrier; ORC1-2, ornithine carriers; PIC, phosphate 1369 
carrier; SAMC, S-adenosylmethionine carrier; TPC, thiamine pyrophosphate carrier; UCP1, 1370 
uncoupling protein; UCP2, uncoupling-like protein 2. CS, cytosol; IS, intermembrane space; 1371 
OM outer membrane; IM inner membrane; MM mitochondrial matrix.  1372 
 1373 
 1374 
FIGURE 2. Structures of the mitochondrial ADP/ATP carrier and the calcium-regulated ATP-1375 
Mg/phosphate carrier and aspartate/glutamate carrier 1376 
Structures of three different mitochondrial carriers, based on PDB entries 1OKC (128) and 1377 
4C9Q (141) for the carrier domains and 4P5W (157) and 4ZCU (59) for the calcium-regulatory 1378 
domains. (A) The mitochondrial ADP/ATP carrier. (B) The mitochondrial ATP-Mg/Pi carrier 1379 
consists of three domains; (i) N-terminal calcium-regulatory domain with four EF-hands (EF1-1380 
4), each binding calcium, (ii) amphipathic helix and (iii) C-terminal carrier domain. (C) The 1381 
aspartate/glutamate carrier also has a three-domain structure, but with a different order; (i) 1382 
N-terminal calcium-regulatory domain, (ii) carrier domain, and (iii) C-terminal amphipathic 1383 
helix. The N-terminal domain has eight EF-hand folds, but only EF-hand 2 is capable of 1384 
binding calcium, which together with EF-hands 1 and 3 forms a calcium-responsive mobile 1385 
unit. EF-hands 4–8 have evolved to form a static dimerization interface. The structures are 1386 
shown in a cartoon representation, colored from the N-terminus in blue to the C-terminus in 1387 
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red. Also shown are the canonical substrates as well as calcium ions (green), magnesium ion 1388 
(chartreuse) and protons (white) in sphere representations. IS, intermembrane space; OM 1389 
outer membrane; IM inner membrane; MM mitochondrial matrix. 1390 
 1391 
 1392 
FIGURE 3. Mitochondrial carriers have a three-fold pseudo-symmetrical structure 1393 
(A) Aligned amino acid sequences of the three repeats of the human ADP/ATP carrier AAC1 1394 
(ANT1). Symmetrically conserved residues are shown in the consensus sequence and as bars, 1395 
when present in at least two out of three repeats. (B) and (C). Comparative model of the 1396 
human ADP/ATP carrier, based on PDB:1OKC (128), viewed from the membrane and the 1397 
intermembrane space, respectively. Shown also is the three-fold pseudo-symmetrical axis, 1398 
symbolized by an equilateral triangle. Odd-numbered (H1, H3, H5), matrix (h12, h34, h56), 1399 
linker (l12, l34, l56) and even-numbered helices (H2, H4, H6) are shown in primary colors for 1400 
the core elements and in gray for the gate elements (142). The black spheres with roman 1401 
numerals show the positions of the three contact points of the substrate binding site (94, 1402 
136). The example, triplet 8-113-210, is indicated by a rectangle across the three repeats in 1403 
(A) and by cyan spheres in (B). IS, intermembrane space; IM inner membrane; MM 1404 
mitochondrial matrix. 1405 
 1406 
 1407 
FIGURE 4. Alternating access transport mechanism for the mitochondrial ADP/ATP carrier. 1408 
Lateral view from the membrane of the mitochondrial ADP/ATP carrier in the cytoplasmic 1409 
state (left) and matrix state (right). Shown are the cytoplasmic state of the bovine ADP/ATP 1410 
carrier (PDB:1OKC) (128) and the matrix state of the ADP/ATP carrier of Thermothelomyces 1411 
thermophila (PDB:6GCI) (142). The water-accessible surfaces are shown in light blue. Also 1412 
indicated are the three main functional features; cytoplasmic gate, substrate binding site 1413 
and matrix gate. The black spheres with roman numerals are the contact points of the 1414 
substrate binding site (94, 136). Shown in green are residues that most likely bind the 1415 
adenine nucleotide substrates. IS, intermembrane space; IM inner membrane; MM 1416 




FIGURE 5. Structural changes in the transport cycle of the human mitochondrial ADP/ATP 1420 
carrier 1421 
(A) View from the intermembrane space and (B) lateral view from the membrane of the 1422 
human ADP/ATP carrier in the cytoplasmic state (left) and matrix state (right). For the import 1423 
of ADP, conformational changes involve the simultaneous outward rotation of the core 1424 
elements, shown in primary colors, and inward rotation of the gate elements, shown in gray, 1425 
in a coordinated way (142). For the export of ATP, the converse happens. Substrate binding 1426 
increases the probability of the state interconversion (156). The structural models are based 1427 
on the structures of the cytoplasmic state of the bovine ADP/ATP carrier (PDB:1OKC) (128) 1428 
and the matrix state of the ADP/ATP carrier of Thermothelomyces thermophila (PDB:6GCI) 1429 
(142). The black spheres with roman numerals are the contact points of the substrate 1430 




FIGURE 6. Pathogenic mutations observed in disease variants of mitochondrial carriers 1435 
Aligned triplets of the 16 mitochondrial carriers associated with developmental, metabolic 1436 
and neuromuscular diseases. The mutations that have a severe effect on function are shown 1437 
in red boxes, whereas those that have milder effects are in yellow. Mutations in blue boxes 1438 
have been identified by genetic analysis, but their effect has not been studied 1439 
experimentally. At the bottom are the three residue numbers that form a triplet in the 1440 
human ADP/ATP carrier (SLC25A4). At the top are the conserved structural and functional 1441 
features of mitochondrial carriers. The triplet is labelled by the one-letter code of the most 1442 
conserved residue or by the most common property: π small amino acids, Φ hydrophobic 1443 
amino acids, ξ hydrophilic amino acids, Ω aromatic amino acids, or by X for any amino acid. 1444 
The black spheres with roman numerals are the contact points of the substrate binding site 1445 
(94, 136). H6 in the ADP/ATP carrier is one residue shorter than other carriers and lacks a 1446 
residue in triplet 90. The matrix loops (indicted by the black bar), as well as the cytoplasmic 1447 
loops and N- and C-terminus have been omitted. 1448 
 1449 
 1450 
FIGURE 7. Small amino acid residues on the odd-numbered helices 1451 
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(A) View from the intermembrane space and (B) lateral view from the membrane of the 1452 
human ADP/ATP carrier in the cytoplasmic state (left) and matrix state (right). The structural 1453 
models are based on the structures of the cytoplasmic state of the bovine ADP/ATP carrier 1454 
(128) and the matrix state of the ADP/ATP carrier of Thermothelomyces thermophila (142). 1455 
The carrier is shown in surface representation and the helices in cartoon representation with 1456 
the core elements in primary colors and the gate elements in gray. Glycine or small residues 1457 
in the interface with the preceding helix are shown in pink, whereas those in the interface 1458 
with the following helix are shown in magenta. The sequence motif is πGπxπGxxπxxxπ 1459 
where G stands for glycine and π for small amino acids (142-144). When the carrier changes 1460 
from the cytoplasmic state to the matrix state the inter-helical distances become smaller on 1461 
the cytoplasmic side of the carrier to facilitate the formation of the cytoplasmic network, 1462 
requiring small residues in the helical interfaces. IS, intermembrane space; IM inner 1463 
membrane; MM mitochondrial matrix. 1464 
 1465 
 1466 
FIGURE 8. Key amino acid residues of the matrix gate 1467 
(A) View from the intermembrane space and (B) lateral view from the membrane of the 1468 
human ADP/ATP carrier in the cytoplasmic state (left) and matrix state (right). The structures 1469 
are described in the legend to FIGURE 7. The key residues shown belong to the sequence 1470 
motif Px[DE]xx[RK]xxxQ on the odd-numbered helices. The proline residues (orange) are 1471 
found at the pronounced kink in the odd-numbered helices, bringing the negatively charged 1472 
(red) and positively charged (blue) residues together to form the matrix network in the 1473 
cytoplasmic state. Underneath one of the salt bridges is a glutamine residue (green) that 1474 
forms hydrogen bonds with both residues (glutamine brace), but in other carriers one, two 1475 
or three glutamine braces can be found (FIGURE 6) (141). IS, intermembrane space; IM inner 1476 
membrane; MM mitochondrial matrix. 1477 
 1478 
 1479 
FIGURE 9. Detailed view of one of the three binding sites for cardiolipin 1480 
One cardiolipin molecule is shown in ball-and-stick representation (cdl802, PDB: 2C3E), 1481 
which is bound on the surface of the carrier and spans the inter-domain interface. The 1482 
carrier is shown in cartoon representation with transmembrane H4 (yellow and gray) and 1483 
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matrix helix h56 (red) enhanced. The two phosphate groups of cardiolipin, which are linked 1484 
by a glycerol moiety, form hydrogen bonds with the amide groups (128) and interact with 1485 
the positively-charged ends of the helix dipoles of the N-terminal ends of the matrix helices 1486 
(cardiolipin binding site I) and the even-numbered helices (cardiolipin binding site II) (24, 1487 
141, 142). The four fatty acid chains of cardiolipin interact with the surface of the carrier in a 1488 
non-specific way via van der Waals interactions (41). Residues in the conserved cardiolipin 1489 
binding site I and II are shown as green and purple sticks, respectively. The interface 1490 
between domain 2 and 3 is shown as a dashed line. 1491 
 1492 
 1493 
FIGURE 10. Amino acid residues involved in cardiolipin binding 1494 
(A) View from the intermembrane space and (B) lateral view from the membrane of the 1495 
human ADP/ATP carrier in the cytoplasmic state (left) and matrix state (right). The structures 1496 
are described in the legend to FIGURE 7. There are three highly conserved binding sites for 1497 
cardiolipin in the mitochondrial ADP/ATP carrier. The residues of cardiolipin binding site I 1498 
belong to the [YF]xG motif (green), whereas those of cardiolipin binding site II belong to the 1499 
[YWF][RK]G motif (purple) (128, 141, 142). IS, intermembrane space; IM inner membrane; 1500 
MM mitochondrial matrix. 1501 
 1502 
 1503 
FIGURE 11. Amino acid residues important for the domain structures on the matrix side 1504 
(A) View from the intermembrane space and (B) lateral view from the membrane of the 1505 
human ADP/ATP carrier in the cytoplasmic state (left) and matrix state (right). The structures 1506 
are described in the legend to FIGURE 7. The positively charged residue of the E-R link I 1507 
(blue), which is located in the matrix gate area, interacts with the negatively charged residue 1508 
of the E-R link II, which is located on the matrix helices. The N-terminal and the fourth 1509 
residues of the linker helices are most commonly glycine residues (magenta), although the 1510 
latter can be replaced by other small residues. IS, intermembrane space; IM inner 1511 
membrane; MM mitochondrial matrix. 1512 
 1513 
 1514 
FIGURE 12. Amino acid residues of the substrate binding site  1515 
 50
(A) View from the intermembrane space and (B) lateral view from the membrane of the 1516 
human ADP/ATP carrier in the cytoplasmic state (left) and matrix state (right). The structures 1517 
are described in the legend to FIGURE 7. The black spheres with roman numerals are the 1518 
contact points of the substrate binding site, which are involved in binding of the substrates 1519 
(94, 136). Other residues in this site (green) may either bind substrate directly, or may allow 1520 
the binding. IS, intermembrane space; IM inner membrane; MM mitochondrial matrix. 1521 
 1522 
 1523 
FIGURE 13. Small amino acid residues on the even-numbered helices  1524 
(A) View from the intermembrane space and (B) lateral view from the membrane of the 1525 
human ADP/ATP carrier in the cytoplasmic state (left) and matrix state (right). The structures 1526 
are described in the legend to FIGURE 7. The small residues (chartreuse) in the interhelical 1527 
interfaces with the odd-number helices facilitate conformational changes. Some residues are 1528 
larger, such as the phenylalanine on H6, because their side chains face the membrane in 1529 




FIGURE 14. Amino acid residues of the cytoplasmic gate 1534 
(A) View from the intermembrane space and (B) lateral view from the membrane of the 1535 
human ADP/ATP carrier in the cytoplasmic state (left) and matrix state (right). The structures 1536 
are described in the legend to FIGURE 7. The key residues belong to the sequence motif 1537 
ξ[FY]xx[YF][DE]xx[RK]. The negatively charged (red) and positively charged (blue) residues 1538 
together form the cytoplasmic network in the matrix state. Underneath are aromatic 1539 
residues (orange), which are part of the hydrophobic plug that closes the cytoplasmic gate. 1540 
The aromatic residue preceding the negatively charged residue is the tyrosine brace (Y-1541 
brace) (142-144). Preceding the aromatic residues are hydrophilic residues (ξ), which form 1542 
the ceiling of the substrate binding site. IS, intermembrane space; IM inner membrane; MM 1543 
























































RK I AKDEGAKAF F KGAWSNVLRG MGGAF -VLVLYDE I KKYV - - - - - - - - 298
ANT1-repeat1 51
ANT1-repeat2 154








FHGLGDC I I K I F KSDGLRGL YQGFNVSVQG I I I YR AAYFGVYDT AKGML PDP - - - - - 205
YKG I I DCVVR I PKEQGF L SFWRGN L ANV I R YF PTQALN F AF KDKYKQL F LGGVDRHK 107
I
ANT1-repeat1 MGDHAWSF L KDF L AGGVAAAVSKT AVAP I ERVKL L LQVQHASKQ I SAEKQ1
Consensus




ANT1-repeat2 - - QFWRYF AGN L ASGGAAGAT SLC F VYPLD F ARTRL AADVGKG - - AAQRE108 153
H5
ANT1-repeat3 - - - KN VH I F VSWMI AQSVT AVAGL VSYPFD T VRRRMMMQSGRK - - GAD I M206 250
A
triplet 8-113-210
IM
IS
MM
l56
l12
l34
Figure 3











